Welcome to our dedicated page for Clorox Co Del SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clorox Company (NYSE: CLX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a consumer products manufacturer in the polish and other sanitation good manufacturing industry. This SEC filings page aggregates those disclosures and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
Key filings for CLX include annual reports on Form 10-K, which typically describe the company’s business segments—Health and Wellness, Household, Lifestyle and International—along with risk factors, discussion of strategy and detailed financial statements. Quarterly reports on Form 10-Q update investors on interim performance, including segment results, margin drivers, cash flow and the impact of initiatives such as the U.S. enterprise resource planning (ERP) transition and portfolio changes like the divestiture of the Better Health Vitamins, Minerals and Supplements business.
Clorox also uses current reports on Form 8-K to disclose material events. Recent 8-K filings have covered quarterly and annual financial results, supplemental financial information, and matters submitted to a shareholder vote at the annual meeting, including director elections, advisory votes on executive compensation and ratification of the independent registered public accounting firm. Other 8-Ks may address leadership changes or other significant corporate developments.
The company’s proxy statement on Form DEF 14A provides additional detail on governance, board composition, executive compensation, strategic priorities such as the IGNITE strategy and oversight of areas like risk management and sustainability. For those interested in ownership and compensation, this document is a primary source.
On this page, filings are updated as they are released to EDGAR. AI-generated highlights and plain-language explanations help clarify complex topics such as non-GAAP measures (for example, organic sales growth, adjusted EBIT and adjusted EPS), the effects of the ERP transition on reported results, and the rationale behind portfolio actions. Users can also review any available insider-related disclosures, such as Form 4 filings, to see reported transactions by directors and officers.
Whether you are analyzing Clorox’s segment performance, reviewing governance practices, or tracking shareholder votes and executive compensation, this filings hub offers structured access to the company’s regulatory record with tools designed to make lengthy documents more approachable.
Clorox director Stephanie Plaines reported two grants of Deferred Stock Units (DSUs) that increase her beneficial ownership. On 08/29/2025 she received 53.9884 DSUs through dividend reinvestment, and on 09/30/2025 she received 212.8954 DSUs in lieu of quarterly director fees. The filing shows the DSUs will be settled 100% in Clorox common stock upon the reporting person’s retirement or other termination, and total reported beneficial ownership after the transactions is 5,413.1984 shares (previously 5,200.303).
Spencer C. Fleischer, a director of Clorox Co. (CLX), reported two acquisitions of deferred stock units under the board’s deferred compensation plan. On 08/29/2025 he received 192.9623 deferred stock units through dividend reinvestment and on 09/30/2025 he received 212.8954 units in lieu of quarterly director fees. The filing states the deferred stock units will be settled 1-for-1 in Clorox common stock upon the reporting person’s retirement or termination. Following the reported transactions, the filing shows total beneficial ownership of 18,799.5242 common shares.
Pierre R. Breber, a Director of Clorox Co. (CLX), reported transactions showing continued ownership and receipt of deferred compensation units. The filing shows indirect ownership of 9,000 shares through a family trust. On 08/29/2025 he acquired 502.2399 deferred stock units via dividend reinvestment under the Independent Directors' Deferred Compensation Plan, and on 09/30/2025 he received 263.5848 deferred stock units in lieu of quarterly director fees. The report states the deferred stock units are 1-for-1 and "will be settled 100% in Clorox stock" upon the reporting person's retirement or other termination of service as a Director. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Laurene E. Peck, Vice President, Chief Accounting Officer & Corporate Controller of Clorox Co. (CLX), reported an acquisition on 09/16/2025 of 1,441 shares of common stock via restricted stock units at an attributable price of $124.85 per share. After the transaction Ms. Peck beneficially owned 5,821 shares directly and 100 shares indirectly through a trust of a parent. The restricted stock units vest in four equal installments on October 5 of 2026, 2027, 2028 and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
Laurene E. Peck, Vice President, Chief Accounting Officer & Corporate Controller of Clorox Co. (CLX), reported an acquisition on 09/16/2025 of 1,441 shares of common stock via restricted stock units at an attributable price of $124.85 per share. After the transaction Ms. Peck beneficially owned 5,821 shares directly and 100 shares indirectly through a trust of a parent. The restricted stock units vest in four equal installments on October 5 of 2026, 2027, 2028 and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025.
Stacey Grier, EVP & Executive Chief of Staff at The Clorox Company (CLX), reported an acquisition of 3,364 restricted stock units on 09/16/2025. The Form 4 shows the units were recorded at a price of $124.85 and, after the transaction, Ms. Grier beneficially owned 23,190 shares. The restricted stock units vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028 and 2029. The filing was signed by an attorney-in-fact on 09/18/2025.
Stacey Grier, EVP & Executive Chief of Staff at The Clorox Company (CLX), reported an acquisition of 3,364 restricted stock units on 09/16/2025. The Form 4 shows the units were recorded at a price of $124.85 and, after the transaction, Ms. Grier beneficially owned 23,190 shares. The restricted stock units vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028 and 2029. The filing was signed by an attorney-in-fact on 09/18/2025.
Angela C. Hilt, Executive Vice President and Chief Legal Officer of The Clorox Company (CLX), reported an acquisition of 7,048 shares of Clorox common stock on 09/16/2025 at a reported price of $124.85 per share. After the reported transaction she beneficially owns 26,881 shares directly. The filing also discloses indirect ownership of 609.663 shares held via the company 401(k) plan. The acquired shares are described as Restricted Stock Units that will vest in four equal installments on October 5 of 2026, 2027, 2028 and 2029.
Angela C. Hilt, Executive Vice President and Chief Legal Officer of The Clorox Company (CLX), reported an acquisition of 7,048 shares of Clorox common stock on 09/16/2025 at a reported price of $124.85 per share. After the reported transaction she beneficially owns 26,881 shares directly. The filing also discloses indirect ownership of 609.663 shares held via the company 401(k) plan. The acquired shares are described as Restricted Stock Units that will vest in four equal installments on October 5 of 2026, 2027, 2028 and 2029.
Marriner Kirsten, Executive Vice President and Chief Administrative Officer of Clorox Co. (CLX), reported an acquisition on 09/16/2025 of 7,689 shares of Clorox common stock at an average price of $124.85 per share, increasing her direct beneficial ownership to 33,994 shares. The filing is a single-person Form 4 signed by an attorney-in-fact on 09/18/2025. The report also discloses that the related Restricted Stock Units will vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028, and 2029.
Marriner Kirsten, Executive Vice President and Chief Administrative Officer of Clorox Co. (CLX), reported an acquisition on 09/16/2025 of 7,689 shares of Clorox common stock at an average price of $124.85 per share, increasing her direct beneficial ownership to 33,994 shares. The filing is a single-person Form 4 signed by an attorney-in-fact on 09/18/2025. The report also discloses that the related Restricted Stock Units will vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028, and 2029.
Chris T. Hyder, EVP—Group President, Health & Hygiene at The Clorox Company (CLX), reported an equity award conversion on 09/16/2025. The filing shows the acquisition of 7,208 shares of Clorox common stock at an indicated price of $124.85 per share, bringing his total beneficial ownership to 29,325 shares. The shares arise from Restricted Stock Units that vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028 and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025. This disclosure records an insider share increase tied to compensation rather than an open-market purchase.
Chris T. Hyder, EVP—Group President, Health & Hygiene at The Clorox Company (CLX), reported an equity award conversion on 09/16/2025. The filing shows the acquisition of 7,208 shares of Clorox common stock at an indicated price of $124.85 per share, bringing his total beneficial ownership to 29,325 shares. The shares arise from Restricted Stock Units that vest in four equal installments, with one-quarter vesting on each of October 5, 2026, 2027, 2028 and 2029. The Form 4 was signed by an attorney-in-fact on 09/18/2025. This disclosure records an insider share increase tied to compensation rather than an open-market purchase.
Nina Barton, Executive Vice President and Group President - Care & Connections at The Clorox Company (CLX), reported an acquisition on 09/16/2025 of 7,208 shares of Clorox common stock at a reported price of $124.85 per share, increasing her beneficial ownership to 28,496 shares. The filing indicates these shares are restricted stock units that will vest in four equal installments on October 5 of 2026, 2027, 2028, and 2029. The Form 4 was submitted by attorney-in-fact Jinho Joo on 09/18/2025.
Nina Barton, Executive Vice President and Group President - Care & Connections at The Clorox Company (CLX), reported an acquisition on 09/16/2025 of 7,208 shares of Clorox common stock at a reported price of $124.85 per share, increasing her beneficial ownership to 28,496 shares. The filing indicates these shares are restricted stock units that will vest in four equal installments on October 5 of 2026, 2027, 2028, and 2029. The Form 4 was submitted by attorney-in-fact Jinho Joo on 09/18/2025.
Eric H. Reynolds, EVP and Chief Operating Officer of The Clorox Company (CLX), reported an acquisition of company common stock on 09/16/2025. The Form 4 shows an acquisition of 9,611 shares at a price of $124.85 per share, bringing his beneficial ownership to 63,832 shares following the transaction. The filing also discloses Restricted Stock Units that vest in four equal installments on October 5 of 2026, 2027, 2028, and 2029. The form was signed by an attorney-in-fact on 09/18/2025.
Eric H. Reynolds, EVP and Chief Operating Officer of The Clorox Company (CLX), reported an acquisition of company common stock on 09/16/2025. The Form 4 shows an acquisition of 9,611 shares at a price of $124.85 per share, bringing his beneficial ownership to 63,832 shares following the transaction. The filing also discloses Restricted Stock Units that vest in four equal installments on October 5 of 2026, 2027, 2028, and 2029. The form was signed by an attorney-in-fact on 09/18/2025.